A new class of drugs targeting the genetic material of skin cancer has been successfully tested in humans for the first time. This opens the way to new treatments for a range of conditions from skin cancers to eye diseases.
The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to new results from a phase I study.
Combining a Wee1 protein inhibitor with the chemotherapy agent gemcitabine reduced sarcoma tumor volume more than did either drug alone.
Researchers have identified the signaling pathway that is overactivated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors, or fulvestrant.
The overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in tumors, tumor inflammation, and metastasis.
The Hsp90 inhibitor ganetespib represents a new treatment opportunity for persons with ALK-positive non-small cell lung cancer (NSCLC).
A monoclonal antibody has been found to be cytotoxic to chronic lymphocytic leukemia B cells while having little effect on normal B cells.
Packaging crystalline arsenic particles in a bubble of fat helps deliver the drug into lymphoma cells without damaging the ovaries.
Inhibiting the protein receptor Mer destroys cancer cells and enhances chemotherapy in both acute myeloid and acute lymphoblastic leukemia.
Researchers at Weill Cornell Medical College report that it is possible to shut down the master regulatory transcription factor Blc6 in DLBCL while not affecting its vital function in the T cells and macrophages needed to support a healthy immune system.
A recent study at the Markey Cancer Center in Kentucky provides insight into potential therapeutic targets to treat aggressive cancer. The study is unique as it comes from the only laboratory in the country to specifically study the metabolic process of triple-negative breast cancer cells.
Researchers have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.
Scientists have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.
Removing the Gfi1 protein from acute lymphoid leukemia (ALL) cells weakened and destroyed the cells in mice, researchers discovered.
Ponatinib (Iclusig), bosutinib (Bosulif), and omacetaxine (Synribo) are enhancing treatment for persons with certain forms of leukemia.
Tiny, water-soluble polymer shells release destructive material into the nucleus of cancer cells while leaving healthy cells untouched.
Grape seed extract inhibited the growth and survival of colorectal cancer cells in advanced disease while leaving healthy cells undisturbed.
Creating T cells that recognize two different antigens on a tumor cell rather than just one could lead to more precisely targeted immunotherapy.
A key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis has been identified, and a connection has been identified between two concepts that are revolutionizing cancer treatment.
The RNA molecule miR-181a appears to be a biomarker for breast cancer metastasis and patient survival, making it a therapeutic target as well.
Usually associated with potentially life-threatening diseases, sickle cells may actually be helpful in the fight against cancer.
A newfound predictor of prostate stem cell antigen (PCSA) expression in bladder cancer could improve treatment efficacy in this disease.
A new experimental drug therapy has been developed to target activated B-cell diffuse large B-cell lymphoma.
Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|